ROTH MKM initiated coverage on Accuray with a new price target
$ARAY
Medical/Dental Instruments
Health Care
ROTH MKM initiated coverage of Accuray with a rating of Buy and set a new price target of $9.00
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 2/13/2024 | $9.00 | Buy | ROTH MKM |
| 6/23/2022 | $7.50 | Buy | B. Riley Securities |
| 12/22/2021 | $7.50 | Buy | Loop Capital |
Strong Service Growth; Debt Refinancing Complete; Company Issues FY26 Guidance MADISON, Wis., Aug. 13, 2025 /PRNewswire/ -- Accuray Incorporated (NASDAQ:ARAY) today reported financial results for the fourth quarter and fiscal 2025, ended June 30, 2025. Key Fiscal Fourth Quarter Highlights Net revenue was $127.5 million, a decrease of 5 percent from the prior year period.Net income was $1.1 million compared to net income of $3.4 million in the prior year period.Adjusted EBITDA was $9.4 million compared to $10.1 million in the prior year period.Order book-to-bill at 1.2Key Fisca
MADISON, Wis., July 30, 2025 /PRNewswire/ -- Accuray Incorporated (NASDAQ:ARAY) will report financial results for the fourth quarter of fiscal year 2025, ended June 30, 2025, during a conference call hosted by company management at 1:30 p.m. PT/4:30 p.m. ET on August 13, 2025. The conference call dial-in numbers are 1-888-999-5318 (USA) or 1-848-280-6460 (international). In addition, a dial-up replay of the conference call will be available approximately one hour after the call's conclusion for one week. The replay number is 1-877-344-7529 (USA) or 1-412-317-0088 (internationa
USA News Group News CommentaryIssued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, June 30, 2025 /PRNewswire/ -- USA News Group News Commentary – The oncology landscape is being pulled in two directions. On one hand, U.S. cancer death rates continue to decline. On the other, global cases are expected to rise sharply—while early-onset diagnoses in younger patients are climbing at a troubling pace. At the same time, proposed federal budget cuts threaten to slash funding for the National Cancer Institute by up to 40%, raising concerns about the future of publicly funded research. With public resources under pressure, much of the innovation burden is shifting to the private sector, where a
8-K - ACCURAY INC (0001138723) (Filer)
S-3 - ACCURAY INC (0001138723) (Filer)
SCHEDULE 13D - ACCURAY INC (0001138723) (Subject)
ROTH MKM initiated coverage of Accuray with a rating of Buy and set a new price target of $9.00
B. Riley Securities initiated coverage of Accuray with a rating of Buy and set a new price target of $7.50
Loop Capital initiated coverage of Accuray with a rating of Buy and set a new price target of $7.50
4 - ACCURAY INC (0001138723) (Issuer)
4 - ACCURAY INC (0001138723) (Issuer)
4 - ACCURAY INC (0001138723) (Issuer)
4 - ACCURAY INC (0001138723) (Issuer)
4 - ACCURAY INC (0001138723) (Issuer)
USA News Group News CommentaryIssued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, June 30, 2025 /PRNewswire/ -- USA News Group News Commentary – The oncology landscape is being pulled in two directions. On one hand, U.S. cancer death rates continue to decline. On the other, global cases are expected to rise sharply—while early-onset diagnoses in younger patients are climbing at a troubling pace. At the same time, proposed federal budget cuts threaten to slash funding for the National Cancer Institute by up to 40%, raising concerns about the future of publicly funded research. With public resources under pressure, much of the innovation burden is shifting to the private sector, where a
MADISON, Wis., June 6, 2025 /PRNewswire/ -- Accuray Incorporated (NASDAQ:ARAY) today announced that, after an extensive review over the last several months, including the evaluation of numerous potential financing partners, it has entered into privately negotiated agreements with the holders of its existing 3.75% senior convertible notes due 2026 (the "Notes") to exchange an aggregate of $82.0 million principal amount of Notes for an aggregate of 8,881,579 shares of the Accuray's common stock (the "Shares"). As part of the exchange consideration, Accuray will pay exchanging holders an aggregate of approximately $68.6 million in cash. The Exchange is expected to close on or about June 11, 202
MADISON, Wis., Jan. 21, 2025 /PRNewswire/ -- Accuray Incorporated (NASDAQ:ARAY) announced today that Leonel Peralta is joining the company as Senior Vice President, Chief Operations Officer, effective February 3, 2025. Mr. Peralta will be responsible for leading worldwide manufacturing operations including driving alignment of operations with corporate business goals, maximizing supply chain profitability and efficiency, and ensuring processes support best-in-class customer service. He will report to Accuray President and Chief Executive Officer Suzanne Winter. Mr. Peralta has
Strong Service Growth; Debt Refinancing Complete; Company Issues FY26 Guidance MADISON, Wis., Aug. 13, 2025 /PRNewswire/ -- Accuray Incorporated (NASDAQ:ARAY) today reported financial results for the fourth quarter and fiscal 2025, ended June 30, 2025. Key Fiscal Fourth Quarter Highlights Net revenue was $127.5 million, a decrease of 5 percent from the prior year period.Net income was $1.1 million compared to net income of $3.4 million in the prior year period.Adjusted EBITDA was $9.4 million compared to $10.1 million in the prior year period.Order book-to-bill at 1.2Key Fisca
MADISON, Wis., July 30, 2025 /PRNewswire/ -- Accuray Incorporated (NASDAQ:ARAY) will report financial results for the fourth quarter of fiscal year 2025, ended June 30, 2025, during a conference call hosted by company management at 1:30 p.m. PT/4:30 p.m. ET on August 13, 2025. The conference call dial-in numbers are 1-888-999-5318 (USA) or 1-848-280-6460 (international). In addition, a dial-up replay of the conference call will be available approximately one hour after the call's conclusion for one week. The replay number is 1-877-344-7529 (USA) or 1-412-317-0088 (internationa
MADISON, Wis., April 30, 2025 /PRNewswire/ -- Accuray Incorporated (NASDAQ:ARAY) today reported financial results for the third quarter ended March 31, 2025. Key Fiscal Third Quarter Highlights: Total net revenue was $113.2 million, an increase of 12 percent year-over-yearNet loss was $1.3 million compared to a net loss of $6.3 million in the prior year periodAdjusted EBITDA was $6.0 million compared to $1.1 million in the prior year period"We achieved a strong third quarter and I am proud of the resiliency of the entire team and their focus on driving actions to mitigate the
SC 13G/A - ACCURAY INC (0001138723) (Subject)
SC 13G - ACCURAY INC (0001138723) (Subject)
SC 13G/A - ACCURAY INC (0001138723) (Subject)